Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal


1Division of Hematology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; 2Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany; 3Servicio Central de Citometría, Centro de Investigación del Càncer (IBMCC; CSC/USAL) and Department of Medicine, University of Salamanca, Salamanca, Spain; 4Division of Hematology, Department of Internal Medicine, University of Istanbul, Turkey; 5III. Medizinische Klinik, Universität Heidelberg, Mannheim, Germany; 6Department of Pathology, University of New Mexico, Albuquerque, USA; 7Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; 8Imagine Institute Université Paris Descartes, Sorbonne, Paris Cité, Centre national de référence des mastocytoses, Paris, France; 9Department of Allergic Diseases, Mayo Clinic, Rochester, USA; 10Hematology Center Karolinska, Karolinska University Hospital, Stockholm, Sweden; 11Division of Hematology-Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, USA; 12Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA; 13Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy; 14Department of Haematology, Guys and St Thomas’ NHS Foundation Trust, Guy’s Hospital, London, UK; 15Division of Allergy and Immunology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA; 16Department of Dermatology, University of Cologne, Cologne, Germany; 17Stanford Cancer Center, Stanford University School of Medicine, Stanford, USA; 18Department of Internal Medicine, Division of Rheumatology, Allergy & Immunology, Virginia Commonwealth University, Richmond, USA; 19Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA; 20Laboratory of Allergic Diseases, NIAID, NIH, Bethesda, USA; 21LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, Cachan, France

Received 19 November 2013; revised 9 January 2014; accepted 17 January 2014

Mast cell leukemia (MCL), the leukemic manifestation of systemic mastocytosis (SM), is characterized by leukemic expansion of immature mast cells (MCs) in the bone marrow (BM) and other internal organs; and a poor prognosis. In a subset of patients, circulating MCs are detectable. A major differential diagnosis to MCL is myelomastocytic leukemia (MML). Although criteria for both MCL and MML have been published, several questions remain concerning terminologies and subvariants. To discuss open issues, the EU/US-consensus group and the European Competence Network on Mastocytosis (ECNM) launched a series of meetings and workshops in 2011–2013. Resulting discussions and outcomes are provided in this article. The group recommends that MML be recognized as a distinct condition defined by mastocytic differentiation in advanced myeloid neoplasms without evidence of SM. The group also proposes that MCL be divided into acute MCL and chronic MCL, based on the presence or absence of C-Findings. In addition, a primary (de novo) form of MCL should be separated from secondary MCL that typically develops in the presence of a known antecedent MC neoplasm, usually aggressive SM (ASM) or MC sarcoma. For MCL, an imminent prephase is also proposed. This prephase represents ASM with rapid progression and 5%–19% MCs in BM smears, which is generally accepted to be of prognostic significance. We recommend that this condition be termed ASM in transformation to MCL (ASM-t). The refined classification of MCL fits within and extends the current WHO classification; and should improve prognostication and patient selection in practice as well as in clinical trials.

Key words: leukemia, mastocytosis, mast cells, KIT D816V, tryptase, prognostication

Introduction

The proposal of the World Health Organization (WHO) divides systemic mastocytosis (SM) into indolent SM (ISM), SM with...
nucleated blood cells [9–12]. In the ‘aleukemic’ variant of MCL, circulating MCs account for <10% [1–4, 13]. In both groups of patients, MCs represent at least 20% of all nucleated cells on BM smears, which remains the primary diagnostic criterion of MCL [1–5].

MCs in MCL are usually immature, sometimes with bi- or multi-lobed nuclei, also termed promastocytes [5]. Metachromatic blasts are also found in these patients. In a very few patients with MCL, more mature forms represent the predominant type of MCs on BM smears. The phenotype of MCs in MCL is similar to that found in patients with ASM [1–4, 10, 14–16]. Notably, MCs in MCL usually express CD9, CD25, CD33, CD44 and CD117 (KIT) [1–4, 14–16]. The CD2 antigen (LFA-2) may also be detected on MCs in MCL [10]. However, the percentage of ‘CD2-positive’ cases is low, and if detected, the levels of CD2 on MCs are usually lower in MCL compared with ISM, suggesting that CD2 expression decreases during malignant progression [14–18]. Tryptase and FcεRI expression may also be decreased in MCs in MCL.

Other markers, like CD52, HLA-DR or CD123, may be expressed at higher levels on MCs in MCL compared with ISM [15, 16]. The Ki-1 antigen (CD30) is usually also expressed more abundantly in MCs in MCL [19, 20]. However, in contrast to CD52, the difference in CD30 expression is only seen in the cytoplasm, but not on the surface of neoplastic MCs [19–21].

With regard to genetic abnormalities, the molecular biology of MCL is similar to that of other SM variants. In many cases, the KIT mutation D816V is detectable in neoplastic cells. However, in contrast to ISM, the frequency of this mutation is lower in MCL (typical ISM: >90% of patients versus MCL: 50–80% of cases). MCs in patients with MCL may also exhibit other mutations at codon 816 of KIT or mutations in other critical regions of KIT [22–27]. In a subset of patients with MCL, no KIT mutations are found [12, 24].

Despite the rarity of the condition, MCL is known to manifest in different forms and variants. Apart from the above-mentioned leukenic and ‘aleukemic’ variants of MCL, the following aspects reflect disease heterogeneity. First, MCL may or may not present with an AHNMD, often in the form of acute myeloid leukemia (AML) [28–30]. These cases (MCL–AML) exhibit a substantial increase (>20%) in myeloblasts and have to be distinguished from patients with myelomastocytic leukemia (MML) where an AML may also be diagnosed, but criteria to diagnose SM are not met. In patients with MCL, a pre-phase of ASM or MC sarcoma may or may not be recognized [31, 32]. Finally, whereas the course of MCL is usually aggressive, a few patients with MCL present with a more indolent, stable clinical course, sometimes even without C-Findings in the initial phase.

As has been stated, an important differential diagnosis to MCL is MML [33–35]. In these MML patients, an underlying advanced myeloid neoplasm (usually with a blast cell excess) is found and is accompanied by a leukemic spread of immature atypical MCs. The criteria to diagnose SM and thus MCL are not fulfilled [33–35]. By definition, MCs in MML account for at least 10% of all nucleated cells in BM or peripheral blood smears [33–35]. In other patients with advanced myeloid neoplasms, MCs also represent a significant population of neoplastic cells, but criteria to diagnose MML are not met (<10% MCs).

All in all, several open questions remain concerning the diagnosis and classification of MCL and MML. To address these questions, the EU/US consensus group and the European Competence Network on Mastocytosis (ECNM) were involved in a series of collaborative meetings and workshops in the years 2011, 2012 and 2013. Outcomes from these discussions and resulting consensus statements are provided in this article.

**basic definitions and diagnostic criteria to separate MCL from MML**

Based on generally accepted criteria, MCL is defined by (i) SM criteria, namely at least one major and one minor or at least three minor SM criteria and (ii) the presence of at least 20% MCs on BM smears [1–4]. Most patients with MCL present with the major SM criterion, namely multifocal sheets and clusters of MCs in BM sections; and in a subgroup of patients, circulating MCs are detectable. If <10% of circulating leukocytes are MCs or no MCs are detected in the blood, the diagnosis is ‘aleukemic MCL.’ [1–4]. Clinical signs and symptoms of organ damage caused by MC infiltration (C-Findings) are usually present. In addition, mediator-related symptoms are often recorded. In most MCL patients, the serum tryptase levels are markedly elevated (>200 ng/ml, often >500 ng/ml) and may increase rapidly (Table 1). MCL may involve several different organ systems. Organ damage is usually found at diagnosis or develops within a short time. Splenomegaly may be present or develops over time. The skin is the only organ spared in MCL. Thus, in the vast majority of MCL cases, no typical maculopapular skin lesions are identified. However, these patients may still experience MC mediator-related skin symptoms such as flushing.

Myelomastocytic leukemia (MML) is a term applied to advanced myeloid (non-MC) neoplasms in which MC differentiation is prominent, but SM criteria are not fulfilled, thereby distinguishing MML from MCL [33, 35]. These patients may suffer from an advanced myelodysplastic syndrome (MDS), usually refractory anemia with an excess of blasts, AML, an accelerated phase of a myeloproliferative neoplasm (MPN) with or without eosinophilia or an MDS/MPN overlap syndrome [33–37]. In MML, MCs comprise at least 10% of all nucleated cells in peripheral blood and/or BM smears. Leukemic MCs in MML are usually immature or are recognized as metachromatic blasts with very low expression of cytoplasmic enzymes (tryptase) and absent or low surface FcεRI. Peripheral blood and BM cells exhibit major signs of dysplasia [33–37]. The major diagnostic criterion of SM (aggregates of >15 MCs in tissue sections) is absent in MML, although a diffuse interstitial increase in MCs is noted. In a vast majority of cases, a complex karyotype is found [33–37]. A KIT mutation may also be detected in these patients (PV, unpublished observation), but codon 816-mutations are typically not detectable in MML [34, 35]. However, MCs in MML may exhibit other clonal lesions typically found in the underlying myeloid neoplasm [33–37]. As in MCL, skin lesions are usually absent. Splenomegaly is found at diagnosis in most MML patients [33–37]. In addition, patients with MML often suffer from mediator-related symptoms or a coagulation disorder associated with major episodes of blood loss [37].
serum tryptase level is also elevated in MML, but is usually below 100 ng/ml (often <50 ng/ml). Table 1 shows typical features of MML and MCL.

To date, the WHO has not recognized MML as a separate entity in their classification proposal. We consider this an important open issue, since these cases and similar conditions are often called ‘unclassifiable’ or ‘not met by WHO criteria’. Therefore, we propose that the WHO should consider the inclusion of MML (as subtype of transformed MDS/AML) in their next update. An important justification is that some of these cases may easily be confused with (acute) basophilic leukemia. Therefore, the diagnosis of MML should be based on a thorough histopathological and immunophenotypic analysis of affected cells [33–37]. An overview of differential diagnoses to MCL and MML is shown in Table 2.

### Table 1. Comparison of clinical and laboratory features typically identified in patients with MCL or MML

<table>
<thead>
<tr>
<th>Feature</th>
<th>Mast cell leukemia (MCL)</th>
<th>Myelomastocytic leukemia (MML)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin lesions</td>
<td>Usually absent</td>
<td>Absent</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>Found in a subset (terminal stage)</td>
<td>Usually present at diagnosis</td>
</tr>
<tr>
<td>Liver involvement with ascites</td>
<td>Often found</td>
<td>Usually not found</td>
</tr>
<tr>
<td>Mediator symptoms</td>
<td>Frequent</td>
<td>Frequent</td>
</tr>
<tr>
<td><strong>Laboratory (blood)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum tryptase (ng/ml)</td>
<td>&gt;200 (often &gt;500)</td>
<td>&lt;100 (often &lt;50)</td>
</tr>
<tr>
<td>Circulating MCs</td>
<td>In a subset of patients</td>
<td>In a subset of patients</td>
</tr>
<tr>
<td>Circulating blasts</td>
<td>No (except MCL–AML)</td>
<td>In a subset of patients</td>
</tr>
<tr>
<td><strong>Bone marrow (BM) findings</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underlying non-MC myeloid neoplasms</td>
<td>No (except MCL-AHNMD)</td>
<td>Yes</td>
</tr>
<tr>
<td>Increase in myeloblasts</td>
<td>Usually not found (except MCL–AHNMD)</td>
<td>Almost always seen</td>
</tr>
<tr>
<td>Clusters and sheets of MCs in BM histology</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Diffuse BM MC infiltrate</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>MCs in BM smears</td>
<td>≥20%</td>
<td>≥10%</td>
</tr>
<tr>
<td>Karyotype</td>
<td>Normal or abnormal with a few lesions¹</td>
<td>Usually complex¹</td>
</tr>
<tr>
<td>MC express CD25</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td><strong>KIT D816V or other codon 816 mutation</strong></td>
<td>Present</td>
<td>Not found</td>
</tr>
<tr>
<td>KIT mutations in non-816-codons</td>
<td>Found in a subset</td>
<td>Found in a subset</td>
</tr>
</tbody>
</table>

¹In MML, the karyotype usually reflects the nature of the underlying disease, whereas no recurrent chromosome abnormalities are known for patients with MCL.

AHNMD, associated clonal hematopoietic non-MC-lineage disease; MCs, mast cells.

staging and grading investigations recommended in patients with MCL and MML

A thorough investigation of the BM remains the key to a correct diagnosis in patients with suspected MCL or MML. Both biopsy material and the aspirate are required to establish a correct diagnosis [1–5, 38]. The biopsy material must undergo a detailed histomorphological, cytochemical and immunohistochemical investigation (see section below). The aspirate smear must be examined for the presence, numbers (percentage) and morphology of MCs, and this analysis is to be carried out at a fair distance from any BM particles or larger cell aggregates [5, 38]. In all patients, the BM aspirate undergoes a detailed cytogenetic analysis, including fluorescence in situ hybridization (FISH), flow cytometry and molecular studies [1–4, 38]. The FISH panel should cover major lesions detectable in MDS and secondary AML. Flow cytometry analysis should be carried out according to guidelines provided by the Spanish Network on Mastocytosis (REMA) [39]. Molecular studies should include an ‘MSD and AML panel’ (major lesions otherwise found in MDS or AML without SM) as well as a mutation analysis of KIT [22, 38]. In a first step, a screen for KIT codon 816 mutations is sufficient [38]. If this analysis is negative, sequencing of the entire KIT gene should be considered. This is of importance in patients with advanced SM and MCL/MML, since several mutations outside of codon 816 may generate kinases that are responsive to treatment with imatinib and/or other KIT-targeting tyrosine kinase inhibitors (TKIs).

For the future, additional assays should be considered in order to define mutation profiles, amplifications or deletions in critical genes and oncogenic pathways that can be detected and may be prognostic in MCL and other forms of advanced SM [40–42].

BM histology and immunophenotyping

A thorough histological and immunohistochemical evaluation of the BM remains an important step toward the diagnosis of SM, including MCL [1–4, 43–45]. The histologic hallmark of MCL is the excessive dense and usually mixed (diffuse and focal) infiltration of the BM by immature neoplastic MCs [1–4, 43–45]. In some patients, the diffuse component of the MC
infiltrate is predominant. However, the major SM criterion will be invariably fulfilled [43–47]. In contrast, in MML, MCs are loosely scattered and form an interstitial (diffuse) BM infiltration pattern, but typically they do not cluster in larger aggregates or sheets. In other words, the major SM criterion is not fulfilled in MML.

A number of markers have been proposed as standard and are to be applied in the immunohistochemical evaluation of the BM in (suspected) MCL and MML. The basic (standard) panel consists of CD34, KIT (CD117), tryptase, CD25, CD30, a megakaryocyte marker such as CD31, CD42 or CD61, a B-cell marker and a T-cell marker [1–4, 38, 43–45, 48]. Other antigens, such as CD2 or chymase, are sometimes also applied. However, these antigens are of little if any value in routine practice. Neoplastic MCs in MCL usually express KIT, low tryptase and low FcεRI, and often also CD25 and CD30, but do not express CD34 (Table 3). In MML, MCs also express KIT and tryptase, but usually stain negative for CD25 [35–37]. Chymase and CD2 are usually not displayed by MCs in MCL and MML. These two antigens may be detected in MCs in patients with ISM and SSM [49, 50]. However, both markers are weakly expressed and therefore are not recommended for grading in daily practice. With regard to CD30, the difficulty is that MCs in ISM may also express some (low) amounts of the antigen, and that in a few patients with MCL, MCs stain negative for CD30 [19, 21]. Some markers, including CD52, HLA-DR and CD123, may also be

### Table 2. Overview of differential diagnoses to consider in patients with suspected mast cell leukemia

<table>
<thead>
<tr>
<th>Differential diagnosis</th>
<th>Typical findings/features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myelomastocytic leukemia (MML)</td>
<td>No SM criteria, MCs ≥10% in BM or PB smears, BM dysplasia, MDS or AML, or chronic myeloid leukemia in blast phase, no KIT mutation in codon 816 found</td>
</tr>
<tr>
<td>Chronic eosinophilic leukemia (CEL)</td>
<td>SM criteria not fulfilled, CD23+ atypical neoplastic MCs found in the BM; but no KIT mutation in codon 816 found, diagnosis=CEL, often with molecular lesions such as fusion genes involving PDGFRa</td>
</tr>
<tr>
<td>Ph+ chronic myeloid leukemia (CML)</td>
<td>BCR/ABL1+, immature metachromatics in CML (accelerated phase or blast phase) are basophils by immunophenotyping; and only a few MCs are found; no mutation in codon 816 of KIT is found</td>
</tr>
<tr>
<td>Acute basophilic leukemia</td>
<td>Massive increase in immature basophils, confirmed by immunophenotyping; no increase in mast cells, no KIT mutation in codon 816 is found</td>
</tr>
<tr>
<td>Chronic basophilic leukemia</td>
<td>Massive increase in basophils, confirmed by immunophenotyping; no increase in mast cells found, no KIT mutation in codon 816 is found</td>
</tr>
</tbody>
</table>

aTesting for the FIP1L1/PDGFRA fusion gene is carried out using PCR and FISH.

bIn a few patients with CML, a so-called basophil-crisis may develop.

cImmunophenotyping should be carried out by both flow cytometry and immunohistochemistry. Valuable markers for basophil-detection and enumeration include CD123 and CD203c (flow cytometry) as well as BB1 and 2D7 (immunohistochemistry).

MCs, mast cells; SM, systemic mastocytosis; BM, bone marrow; PB, peripheral blood; PDGFR, platelet-derived growth factor receptor.

### Table 3. Phenotypic heterogeneity of mast cells (MCs) in MC disorders

<table>
<thead>
<tr>
<th>Marker</th>
<th>Markers expressed in MCs in</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal BM</td>
</tr>
<tr>
<td>CD34/HPCA-1</td>
<td>–</td>
</tr>
<tr>
<td>CD117/KIT</td>
<td>+</td>
</tr>
<tr>
<td>Tryptase</td>
<td>+</td>
</tr>
<tr>
<td>CD33/Siglec-3</td>
<td>+</td>
</tr>
<tr>
<td>CD123/IL-3RA</td>
<td>–</td>
</tr>
<tr>
<td>CD2/LFA-2</td>
<td>–</td>
</tr>
<tr>
<td>CD25/IL-2RA</td>
<td>–</td>
</tr>
<tr>
<td>CD30/KI-1</td>
<td>–</td>
</tr>
<tr>
<td>FcεRI</td>
<td>+</td>
</tr>
</tbody>
</table>

aIn a few cases, one of the two markers, either CD2 or CD25 may be expressed in neoplastic MCs in MML. +, expressed in MCs in almost all (>90% of) SM patients, +/-, expressed in a majority of MCs in a considerable subset of SM patients; –/+, expressed in a minority of MCs in a smaller subset of SM patients; –, not expressed in neoplastic MCs in SM patients.

BM, bone marrow; HPCA-1, human precursor cell antigen-1; IL-3, interleukin-3; ISM, indolent systemic mastocytosis; SSM, smouldering SM; ASM, aggressive SM; MCL, mast cell leukemia; MML, myelomastocytic leukemia; n.k., not known.
expressed more abundantly in MCs in ASM and MCL. However, again, no absolute correlations are found, and results obtained should be interpreted with caution. Ki-67 is a well-established proliferation marker that is usually not expressed in neoplastic MCs in SM as MCs are usually non-proliferating cells. However, in MCL patients with rapidly progressing disease, the number of Ki-67-positive MCs is markedly increased [51].

**the BM smear: recommended standards and caveats**

Major pre-analytical pitfalls include a ‘dry tap’ (*punctio sicca*), a major ‘contamination’ of the aspirate sample with peripheral blood cells and a suboptimal quality of the smear. With regard to aspiration, it is sometimes difficult to perform a marrow-rich aspirate in advanced SM because of BM fibrosis or densely packed cells (high infiltration grade). Therefore, the consensus group recommends that for all patients with (suspected) advanced SM, a touch-preparation is to be carried out from the BM biopsy material. Even if a smear is prepared, the ‘touch-prep-slides’ should also be sent to all involved diagnostic laboratories. In the case of a major blood contamination, which is usually seen immediately on the smears (none to few BM particles on the slides), a second aspiration from a different location and with a new needle is recommended. The smears should always be checked to guarantee optimal quality after aspiration and should then be air-dried before being processed and stained. It is mandatory that the staff of each involved laboratory, including the flow cytometry-team and the pathologist, receives unstained good-quality BM aspirate smears (at least two slides) together with the BM sample(s) that should be processed and analyzed. In some cases, a second BM biopsy or/and aspirate may be required.

**morphologically identifiable stages of MC differentiation/maturation**

A morphologic classification of neoplastic MCs has been published and is a generally accepted standard of evaluation of BM smears in SM [5]. The classification is based on distinct stages of maturation of normal MCs and corresponding morphological stages of MC maturation detectable in BM smears in SM [5]. Based on these morphologies, the following subtypes of MCs have been defined: (i) typical mature tissue MCs with a round central nucleus, (ii) atypical MCs type I, (iii) atypical MCs type II and (iv) metachromatically granulated blast cells (metachromatic blasts) (Figure 1). Morphologic criteria defining the various types of MCs are depicted in Table 4. It is important that these criteria are applied in all patients using a ‘good-quality BM smear’ in order to grade MC populations correctly [5, 38]. In addition, it is important to define the numbers of MCs in BM smears accurately. A total of at least 200–400 nucleated cells should be counted as the basis of enumeration and grading of MCs in BM smears, and such enumeration should be carried out in areas in which no packed cells or BM particles are observed [38]. An increase in immature atypical MCs or metachromatic blasts over 10% of all MCs on a BM

![Figure 1](image.png)
smear must be regarded as ‘high grade morphology’. Flow cytometry is usually helpful to confirm the numbers and percentage of MCs in the BM and to determine the degree of maturation of MCs and MC-committed precursor cells [52].

### Clinical significance of cytological staging and grading

In most patients with MCL, MCs are rather immature. These cells often represent metachromatic blasts or atypical MCs type II (promastocytes) (Table 4). However, there are a few patients with MCL, in whom most MCs represent more mature cells (Figure 2). A number of previous studies have shown that the percentage of MCs in BM smears recorded in SM is of prognostic significance [5]. In MCL, MCs comprise at least 20% of all nucleated cells on BM smears. However, even an increase to ≥5% may be prognostically unfavorable compared with patients with <5% MCs in BM smears. These patients (5%–19% MC) are usually suffering from ASM with rapid progression, and several of these patients may progress to overt MCL within a relatively short time (usually within several months). Therefore, the consensus group judged it appropriate to propose de novo diagnosis. One important concept is that MCL may develop as either a de novo disease or as a secondary leukemia following ASM or MC sarcoma. Based on these observations, we believe it justified to separate a primary (de novo) variant of MCL from secondary MCL (Table 5). Finally, as mentioned above, in a few cases of MCL, the course of the disease may be less aggressive and more chronic even if circulating MCs are detectable. These cases may later progress and the overall outcome may be limited. However, the overall prognosis may still be better than in the acute variant of MCL, especially when no C-Findings are detectable.

### Proposed categories of MCL

Based on WHO criteria [1–5], MCL is divided into a leukemic variant (circulating MCs >10%) and an aleukemic variant of MCL (circulating MCs <10%). In both categories, the outcome is poor. During the past few years, additional information concerning the biology of MCL has been discussed at expert meetings. One important concept is that MCL may develop as either a de novo disease or as a secondary leukemia following ASM or MC sarcoma. Based on these observations, we believe it justified to separate a primary (de novo) variant of MCL from secondary MCL (Table 5). Finally, as mentioned above, in a few cases of MCL, the course of the disease may be less aggressive and more chronic even if circulating MCs are detectable. These cases may later progress and the overall outcome may be limited. However, the overall prognosis may still be better than in the acute variant of MCL, especially when no C-Findings are detectable.

We therefore propose to differentiate between chronic MCL without C-Findings and acute MCL with C-Findings (Table 5). In the final diagnosis, one, two or all three defining features should be considered, depending on available information and the clinical situation and laboratory findings. Likewise, a patient could suffer from secondary acute aleukemic MCL or from primary chronic MCL.

### Proposed variants of MML

As mentioned above, MML has to be separated from any type of SM, including MCL. Rather, in patients with MML, another
Figure 2. Typical morphological features of mast cells observed in patients with acute or chronic mast cell leukemia (MCL). Wright–Giemsa-stained bone marrow smears obtained from two patients with acute MCL (A) and two patients with chronic MCL (B). Note the immature morphology of several of the mast cells (MCs) in the patients with acute MCL (A). Some of these MCs exhibit bi-lobed nuclei. In contrast, in patients with chronic MCL, most MCs exhibit a mature morphology, either with spindle-shaped forms (upper panel in B) or with round and well-granulated MCs (lower panel in B), whereas immature forms are very rare or even not detectable in these patients.

Figure 3. Flow cytometric analysis of mast cell differentiation profiles in the bone marrow of patients with MCL. Bone marrow aspirate samples were obtained from a patient with acute MCL (upper panels; the same case shown in the lower left panel of Figure 2) and chronic MCL (lower panels; case shown in the lower right panel of Figure 2). Expression of cell surface antigens on KIT+ (CD117+) mast cells (events colored blue, green and red) was determined by monoclonal antibodies and multicolor flow cytometry. Mast cells in MCL typically express KIT and lack CD34 (left panels). Mast cells usually also express tryptase and CD203c. However, mast cells in MCL express only low levels of (or no detectable) high-affinity IgE receptors (FceRI) and only low levels of CD2, whereas CD25 is often expressed on mast cells in MCL.
underlying (advanced) myeloid neoplasm is identified and serves as a major diagnostic criterion of MML. Therefore, MML can be naturally divided into subcategories based on the type of the underlying myeloid neoplasm. In addition, patients with MML could also be split into leukemic and aleukemic variants, similar to MCL, although the clinical implication of these subtypes remains unknown. Otherwise, MML should always be regarded as a secondary condition. Also, as mentioned above, MML should not be regarded as a subvariant of MCL or SM.

**imminent prephases of MCL and MML: definition and proposed terminology**

The group also discussed potential imminent prephases of MCL and MML. In the case of MCL, it is important to note that the prognosis clearly correlates with the numbers of atypical immature MCs recorded in BM smears, even when MCs comprise <20%. Although this correlation was described in 2001 [5], the related conditions have not been addressed by any nomenclature to date. The prognosis may be particularly poor if the percentage of MCs in the BM smear increases to 5% or more of all nucleated BM cells. In many of these cases, ASM may progress to overt MCL within a relatively short time (months). To address this important point, the group considered to define this special situation and to introduce the term ‘ASM transformation’ (ASM-t) for these patients. In other words, the condition ASM-t is defined by SM criteria, C-Findings and a MC percentage of 5%–19% of all nucleated cells in BM smears.

In MML, the situation is similar, but the prognostic implications of an increased MC percentage in the range of 5%–9% have not been established in the same way as for ASM-t, although the condition has been described [53, 54]. After a thorough discussion through several meetings, the group concluded that it is too early to define this condition using a special term, such as myelomastocytosis (MM) or ‘myelomastocytic’ transformation. For the moment, the condition should thus be described as a secondary clonal increase in immature atypical MCs (metachromatic cells) neither meeting the criteria of SM/MCL nor criteria of MML. Finally, several differential diagnoses have to be considered in patients with apparently unclassifiable myeloid neoplasm and an increase in immature metachromatic cells [46, 53, 55] (Table 2).

**follow-up and associated parameters**

In an early phase of diagnosis, it is essential to monitor several disease-specific parameters, especially if the diagnosis is in question or a (potential) prephase of MCL (ASM-t) or MML has been diagnosed. In these patients, it is important to record the serum tryptase level and the blood counts (in close time intervals) in order to recognize transformation into MCL and to delineate between more chronic and acute disease variants. The standard assay for measurement of tryptase has a maximum value of 200 ng/ml. However, patients with MCL usually show levels well above this maximum value. Therefore, careful dilution of serum samples may be necessary for accurate measurement of tryptase levels. A rapid increase in MCs in the BM or blood; and rapid increase in serum tryptase (e.g. by 100 ng/ml within a few weeks) are indicative of acute MCL. Progression or occurrence of one or more C-Finding(s) is also indicative of acute MCL. Treatment response criteria are available [11, 38, 56] and work for MCL, and similar criteria can also be applied for MML, although the value of these criteria in MML has not been formally proven yet. The serum tryptase level remains a key follow-up and treatment-response parameter in MCL. Other useful parameters in MCL may be alkaline phosphatase (if initially elevated), eosinophil counts and MC numbers in the blood and BM.

**conclusions and future perspectives**

Because of the rarity and complexity of the disease, immaturity of clonal cells, and absence of skin involvement, the diagnosis of MCL and MML is a challenge in clinical hematology. Although criteria for MCL and MML are available, several questions remain concerning subvariants, criteria, the diagnostic interface, prephases of disease and the differential diagnoses. To address these questions, the EU/US consensus group and the ECNM have initiated a discussion-forum in which updated recommendations, refined criteria and classification proposals have been developed. The resulting refinements and updated classification should facilitate diagnostic studies and help in reaching a correct final diagnosis in patients with these disorders. For the future, we hope that the WHO will consider these proposals and implement these refinements in the updated classification of hematopoietic malignancies.
Supported by: Fonds zur Förderung der Wissenschaftlichen Forschung in Österreich, grants #SFB-F46-10 and #SFB-F47-04, a research grant of The Mastocytosis Society (TMS) and in part by the NIAID Division of Intramural Research.

acknowledgements

We like to thank Sabine Cerny-Reiterer, Barbara Peter, Ghaiith Wedeh and Emir Hadzijusufovic for their helpful support and for helpful discussions.

funding

No funding was received for this study.

disclosure

The authors have declared no conflicts of interest.

references


New agents for prostate cancer

N. Agarwal1, G. Di Lorenzo2, G. Sonpavde3 & J. Bellmunt4,5*

1Division of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, USA; 2Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Napoli, Italy; 3Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham; 4Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, USA and; 5University Hospital del Mar-IMIM, Barcelona, Spain

Received 27 July 2013; revised 12 October 2013 & 8 December 2013; accepted 7 January 2014

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized by the arrival of multiple novel agents in the past 2 years. Immunotherapy in the form of sipuleucel-T, androgen axis inhibitors, cabazitaxel, and a radiopharmaceutical, radium-223, have all yielded incremental extensions of survival and have been recently approved. A number of other agents appear promising in early studies, suggesting that the armamentarium against castrate-resistant prostate cancer is likely to continue to expand. Emerging androgen pathway inhibitors include androgen synthesis inhibitors (TAK700), androgen receptor inhibitors (ARN-509, ODM-201), AR DNA binding domain inhibitors (EPI-001), selective AR downregulators or SARDs (AZD-3514), and agents that inhibit both androgen synthesis and receptor binding (TOK-001/galeterone). Promising immunotherapeutic agents include poviuros vaccines and CTLA-4 inhibitor (ipilimumab). Biologic agents

*Correspondence to: Dr Joaquim Bellmunt, Department of Medical Oncology, University Hospital del Mar, Paseig Maritim 25-29, Barcelona, Spain. Tel: +34-932-483137; Fax: +34-932-483366; E-mail joaquim.bellmunt@gmail.com

© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

doi:10.1093/annonc/mdu038

Published online 20 March 2014